HCW Biologics regains Nasdaq compliance
Seeking Alpha ·
HCW Biologics ( HCWB ) regained compliance with Nasdaq's minimum bid price requirement. The company will remain under a mandatory Nasdaq monitoring period through June 17, 2027. To support long-term compliance, HCW Biologics will implement a 1-for-6 reverse stock split effective June 30, 2026. The compliance determination follows the Nasdaq Hearings Panel's June 29, 2026 decision. Most and least shorted healthcare stocks with market cap up to $2B at the end of May HCW Biologics takes back rights to commercial-ready reagents Seeking Alpha’s Quant Rating on HCW Biologics Historical earnings data for HCW Biologics
DYAX Investor Sentiment
Bullish (Long) 54% · Bearish (Short) 46%
221 participants
Related News
- Harmony Gold says production guidance met for 11th straight year
- iPhone users could save money under App Store crackdown
- Amazon’s AWS commits $1 billion toward new unit for embedded AI engineers
- Tech Weekly: Tesla's FSD tech up for debate, Shell unveils concept car
- AI, chip stocks continue to rebound, boosting Wall Street higher
- Global Performance Consultancy Launches New Sports Division Designed to Build the Infrastructure that Winning Requires